SEC Form 4 · accession 0001209191-16-092753
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Susan M Kanaya
Officer — SVP, Finance, CFO and Sec.
Period of report
Jan 15, 2016
Accepted (ET)
Jan 20, 2016 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2016 | M | 300 | $2.00 | A | 300 | D | |
| Common StockF2 | Jan 15, 2016 | S | 300 | $4.00 | D | 0 | D | |
| Common Stock | Jan 19, 2016 | M | 6,134 | $2.00 | A | 6,134 | D | |
| Common StockF2,F3 | Jan 19, 2016 | S | 6,134 | $4.0472 | D | 0 | D | |
| Common Stock | Jan 20, 2016 | M | 14,971 | $2.00 | A | 14,971 | D | |
| Common StockF2,F4 | Jan 20, 2016 | S | 14,971 | $4.0973 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6,F5 | $2.00 | Jan 15, 2016 | M | 300 | D | Feb 9, 2006 | Feb 9, 2016 | Common Stock | 300 | 46,869 | D |
| Stock Option (right to buy)F6,F5 | $2.00 | Jan 19, 2016 | M | 6,134 | D | Feb 9, 2006 | Feb 9, 2016 | Common Stock | 6,134 | 40,735 | D |
| Stock Option (right to buy)F6,F5 | $2.00 | Jan 20, 2016 | M | 14,971 | D | Feb 9, 2006 | Feb 9, 2016 | Common Stock | 14,971 | 25,764 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a December 2014 Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Shares sold are associated with stock options which will expire in February 2016.
- F3Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $4.00 to $4.16 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F4Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $4.00 to $4.22 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F5As of January 15, 2016 and prior to this transaction, the option fully vested.
- F6Not applicable.